Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Inthavaroros Rd. Sriphum, Maung Chiang Mai, Chiang Mai 50200, Thailand.
Medicina (Kaunas). 2021 Nov 11;57(11):1229. doi: 10.3390/medicina57111229.
: Real-world studies are limited regarding the effectiveness of SCIT on allergic rhinitis (AR) with and without asthma and the cost of medication in Thailand. Moreover, limited data exist regarding the effectiveness of SCIT on worldwide upper respiratory tract infection (URTI). Therefore, the objective of this study was to compare the medication costs, rate of AR and asthma exacerbations, and rate of URTI in AR with or without asthma subjects before and during three years after receiving the maintenance phase of SCIT, compared with a standard usual care (SUC) group. : A real-world retrospective study was conducted in AR subjects with or without asthma. From January 2001 to December 2018, 24 subjects with or without asthma received SCIT added to SUC, and 16 subjects were treated with SUC only at the Allergy and Chest Clinic of Chiang Mai Ram Hospital, Chiang Mai, Thailand. The cost of medication was recorded. AR and asthma exacerbations and URTI events were also collected. From between-group comparisons, the cost of medication (THB) in the SCIT group at the one-, two-, and three-year follow up was significantly lower (587.4 (348.3-1374.6) vs. 1562.4 (1315.1-1857.3), < 0.001, 501.2 (302.9-839.0) vs. 1728.3 (1190.0-2236.1), < 0.001, and 372.4 (284.8-752.4) vs. 1500.3 (1217.9-1748.9), < 0.001, respectively)), and AR and asthma exacerbations were significantly reduced at the three-year follow-up. From within-group comparisons, the cost of medication (THB) and AR and asthma exacerbations were significantly lower in the SCIT group at the one-, two-, and three-year follow-up. The URTI event was significantly reduced in the SCIT group at the two- and three-year follow-up. : SCIT in subjects with AR with or without asthma was associated with a significantly reduced cost of medication, rates of AR and asthma exacerbations, and URTI events in the long term.
: 关于变应性鼻炎（AR）伴或不伴哮喘患者接受皮下免疫治疗（SCIT）的有效性以及泰国药物治疗费用的真实世界研究有限，而且关于 SCIT 对全球上呼吸道感染（URTI）的有效性的相关数据也有限。因此，本研究的目的是比较接受 SCIT 维持治疗前后 3 年期间 AR 伴或不伴哮喘患者的药物治疗费用、AR 和哮喘加重率以及 URTI 发生率，并与标准常规护理（SUC）组进行比较。 : 这是一项在 AR 伴或不伴哮喘患者中进行的真实世界回顾性研究。2001 年 1 月至 2018 年 12 月，24 例 AR 伴或不伴哮喘患者在清迈 Ram 医院过敏和胸部诊所同时接受了 SCIT 和 SUC 治疗，16 例患者仅接受 SUC 治疗。记录了药物治疗费用。还收集了 AR 和哮喘加重以及 URTI 事件。从组间比较来看，SCIT 组在第 1、2 和 3 年的药物治疗费用（泰铢）显著降低（587.4（348.3-1374.6）比 1562.4（1315.1-1857.3），<0.001，501.2（302.9-839.0）比 1728.3（1190.0-2236.1），<0.001，和 372.4（284.8-752.4）比 1500.3（1217.9-1748.9），<0.001），并且在第 3 年的随访中，AR 和哮喘加重明显减少。从组内比较来看，SCIT 组在第 1、2 和 3 年的药物治疗费用（泰铢）和 AR 和哮喘加重均显著降低。在第 2 年和第 3 年的随访中，SCIT 组的 URTI 事件明显减少。 : 在 AR 伴或不伴哮喘患者中，SCIT 治疗与长期药物治疗费用显著降低、AR 和哮喘加重率以及 URTI 事件减少相关。
